Bcare Grants

Funding Body

Project Title

Date Awarded

Role in Grant

Co-applicants

North Bristol NHS Trust

Flexibility and sustainability funding for NIHR pump priming activities

01/01/2008

Principal Investigator

AP MacGowan, AM Lovering

Western CLRN

Infrastructure funding

01/01/2008

Principal Investigator

AP MacGowan, AM Lovering

Western CLRN

Key support for funding equipment

01/01/2008

Principal Investigator

AM Lovering, KE Bowker

NIHR

Programme Grant: Blood stream infection: focus on outcomes

09/10/2008

Principal Investigator

AP MacGowan

NIHR-HTA

HTA: The diagnosis of urinary tract infection in young children (DUTY) study

01/01/2009

Co-applicant

AP MacGowan

EU/European CDC Development of a European susceptibility testing method 01/01/2008 Co-applicant AP MacGowan
North Bristol NHS Trust Flexibility and sustainability funding for NIHR pump priming activities 01/01/2009 Principal Investigator AP MacGowan, AM Lovering
NISCHR Research group: Microbiology and Infection Translational Research Group 01/01/2010 Co-applicant AP MacGowan, AM Lovering
Cerexa Pharmacodynamic assessment of the combination of ceftaroline plus NXL 104 against wild type and multi-resistant Enterobacteriacaea studied in an in vitro pharmacokinetic infection model 01/01/2009 Principal Investigator AP MacGowan, KE Bowker
Protez Pharmaceuticals Inc Pharmacodynamic assessment of PZ601 against Staphylococcus aureus and Enterobacteriacae: antibacterial effects of simulated human doses and assessment of T>MIC relationships 01/02/2008 Principal Investigator AP MacGowan, KE Bowker
Bayer Schering Healthcare Studies on sequential fluoroquinolone dosing in an in vitro pharmacokinetic model of infection: impact on antibacterial effect and risk of emergence of resistance 01/04/2007 Principal Investigator AP MacGowan, KE Bowker
Astellas Pharma Europe Ltd Comparative pharmacodynamics of telavancin, daptomycin, linezolid, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection 01/08/2007 Principal Investigator AP MacGowan, KE Bowker
Johnson & Johnson Pharmacodynamic assessment of doripenem and imipenem against Pseudomonas aeruginosa and Acinetobacter species: impact of T>MIC 01/07/2007 Principal Investigator AP MacGowan, KE Bowker
Basilea Pharmaceutica In vitro study to investigate the potency of new dihydrofolate reductase inhibitors against clinical Gram positive pathogens 01/05/2007 Principal Investigator AP MacGowan, KE Bowker
Mayne Pharma plc A Phase 1 randomised double blind cross over study to compare the pharmacokinetic/pharmacodynamic and safety characteristics of targocid with Mayne teicoplanin administered as single iv doses in healthy volunteers 01/07/2006 Principal Investigator AP MacGowan, AM Lovering
Hoffman La Roche The pharmacodynamics of the antibacterial effect and emergence of resistance to R04906463/CS-023/tomopenem in an in vitro pharmacokinetic model of S.aureus infection 01/05/2005 Principal Investigator AP MacGowan, KE Bowker
Basilea Pharmaceutica The in vitro potency of a novel Blactam/Blactamase inhibitor combination against P.aeruginosa, Enterobacter cloacae, Klebsiella Pneumoniae and E.coli using an in vitro pharmacokinetic model 01/07/2006 Principal Investigator AP MacGowan, KE Bowker
Basilea Pharmaceutica In vitro study to investigate the potency of BAL 30072 against clinical strains of Enterobacter species and Gram negative rods with defined resistance mechanisms 01/10/2006 Principal Investigator AP MacGowan, KE Bowker
Cubist Pharmaceuticals Determination of daptomycin and vancomycin MIC, MBC and kill curves on US MRSA isolates 01/08/2006 Co-Principal Investigator AP MacGowan, TR Walsh
Merck Sharp & Dohme The antibacterial effects of ceftriaxone, ertapenem and piperacillin-tazobactam against extended spectrum Blactamase strains of Enterobacteriacae in an in vitro pharmacokinetic model 01/01/2005 Principal Investigator AP MacGOwan, AR Noel, KE Bowker
GR Micro Ltd Comparative pharmacodynamics of daptomycin, vancomycin and teicoplanin in an in vitro pharmacokinetic model of infection 01/02/2005 Principal Investigator AP MacGowan, KE Bowker, AR Noel
European Union DGSANCO/European CDC Antibiotic susceptibility proposal 790806 01/01/2005 Co-applicant AP MacGowan
Department of Health Sentinel and population surveillance of Panton-Valentine leucocidin-positive S.aureus and community acquired MRA 01/06/2007 Co-Principal Investigator AM Lovering, AP MacGowan
National School for Primary Care Research, Department of Health Primary Care antibiotic prescribing and antimicrobial resistance (PCAAR) 01/02/2007 Co-Principal Investigator AM Lovering, AP MacGowan
Showering Fund An investigation of the reservoir of antibiotic resistance genes by the commercial bacteria of healthy community volunteers and how this impacts on the prevalence of antibiotic resistance in bacteria associated with UTI 01/07/2008 Principal Investigator AM Lovering
North Bristol NHS Trust Research Foundation Determination of protein binding of vancomycin in a general hospital patient population 01/06/2007 Principal Investigator AM Lovering
North Bristol NHS Trust Research Foundation An evaluation of the Bronkotest system for identification of respiratory infection 01/06/2007 Principal Investigator AM Lovering
Basilea The in vitro activity of BAL 30072 using simulated human serum pharmacokinetics against multiresistant Pseudomonas aeruginosa 01/01/2009 Co-Principal Investigator KE Bowker